[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362703-105":59,"doc-detail-362703-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","extracellular-vesicles-as-emerging-drug-delivery-platforms-in-triple-negative-breast-cancer-a-systematic-review","Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review","","Breast cancer is the most prevalent malignancy among women, and triple-negative breast cancer (TNBC) is its most aggressive subtype. With no standard targeted therapies, treatment relies mainly on chemotherapy, which is limited by poor tumor targeting and significant off-target toxicity. This systematic review evaluates EV-based drug delivery systems for TNBC using 17 studies published from 2020–2024 across Scopus, PubMed, and Web of Science. EV cargos include chemotherapeutic agents and nucleic acids. Findings integrate in vitro and in vivo evidence of efficacy, engineering approaches for improved targeting, and the need for standardized EV isolation, characterization, and reporting protocols, while addressing clinical translation challenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/extracellular-vesicles-as-emerging-drug-delivery-platforms-in-triple-negative-breast-cancer-a-systematic-review/362703/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/extracellular-vesicles-as-emerging-drug-delivery-platforms-in-triple-negative-breast-cancer-a-systematic-review/362703.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemotherapy still the primary treatment for TNBC?","Question",{"text":112,"@type":113},"TNBC lacks standard targeted receptors, so chemotherapy remains the main strategy. However, chemotherapy faces poor tumor targeting, rapid systemic clearance, and significant off-target toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic cargos do extracellular vesicles deliver in TNBC?",{"text":117,"@type":113},"Extracellular vesicles (EVs) can transport diverse therapeutic cargos, including chemotherapeutic agents and nucleic acids such as DNA and RNA, enabling targeted anti-tumor delivery.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges affect clinical translation of EV-based therapies?",{"text":121,"@type":113},"Despite promising efficacy, clinical translation is hindered by technical limitations and inconsistent reporting, emphasizing the need for standardized protocols for EV isolation and characterization.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362703,1790928269,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nExtracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review  \nJiao Tian 1 , 2 , Yun Zhi Chin 3 , Min Hwei Ng 1 , Kok Lun Pang4 , Jia Xian Law 1  \n1Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2Department of Clinical Medicine, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People’s Republic of China; 3Division of Applied Biomedical Science and Biotechnology, School of Health Science, IMU University, Kuala Lumpur, Malaysia; 4Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, Malaysia  \nCorrespondence: Jia Xian Law, Email [lawjx@hctm.ukm.edu.my](lawjx@hctm.ukm.edu.my)  \n\n| Abstract: Breast cancer is the most prevalent malignancy among women, with triple-negative breast cancer (TNBC) being the most aggressive subtype. The lack of standard targeted therapies necessitates reliance on chemotherapy, which often suffers from poor targeting and significant off-target toxicity. This systematic review evaluates the therapeutic potential of drug delivery systems based on extracellular vesicles (EVs) for TNBC using 17 studies from 2020 to 2024 published in Scopus, PubMed, and Web of Science. Thereview discusses the diverse therapeutic cargos delivered by EVs, including chemotherapeutic agents and nucleic acids, while emphasizing the need for standardized protocols to facilitate EV isolation and characterization. Key findings provide both in vitro and in vivo evidence of the efficacy of EV-based therapies against TNBC cell lines and animal models, alongside insights into engineering strategies that enhance targeting specificity. Despite the promising findings, challenges remain in clinical translation, such as technical limitations and inconsistent reporting. The results underscore the potential of EVs to revolutionize TNBC treatment strategies, paving the way for more effective therapeutic options.\u003Cbr>Keywords: exosome, breast cancer, drug delivery system, precision medicine, chemotherapy |\n| --- |\n| Introduction\u003Cbr>Breast cancer is the most prevalent cancer in women globally, and triple-negative breast cancer (TNBC) is its most aggressive and metastatic subtype.1–4 Since targeted receptors are absent, chemotherapy is the primary treatment strategy.5–9 However, TNBC has high rates of recurrence, poor prognosis, and unfavorable survival outcomes.10–14 Clinical efficacy of chemotherapeutics is hampered by several limitations, including poor tumor targeting, rapid systemic clearance, and substantial off-target toxicity.15–21\u003Cbr>Precision medicine has been developed recently and represents a paradigm transformation in oncology to provide more efficient and customized treatment approaches.22–27 In this context, extracellular vesicles (EVs) have garnered increasing attention as a novel drug delivery platform.21,28–32 EVs are nanoscale vesicles found in almost all kinds of cells in the body and are important as mediators of intercellular communication through the transport of nucleic acids (DNAs and RNAs), proteins, and lipids.33–37 Due to their intrinsic biocompatibility, low immunogenicity, natural targeting ability, and adaptability, EVs are excellent candidates for precision medicine.29,38–40 Increasing evidence supports this potential, demonstrating their ability to selectively deliver therapeutic payloads to target cells, thereby enhancing anti-tumor efficacy while minimizing systemic toxicity and off-target effects.41–47\u003Cbr>This systematic review examines the therapeutic potential of EV-based drug delivery systems in TNBC, reflecting the growing interest and promising applications of EV-based therapeutics in cancer treatment. Based on an assessment of 17 eligible studies, this review provides: (1) an evaluation ofthe in vitro and in vivo efficacy of EV-base","cbCaig81PpRTYLnT","https://ap.wps.com/l/cbCaig81PpRTYLnT","pdf",3821683,22,"English","# Introduction\n## Precision medicine and extracellular vesicles\n# Abstract\n## Therapeutic potential and study scope\n# Methods\n## Systematic review approach","[{\"question\":\"Why is chemotherapy still the primary treatment for TNBC?\",\"answer\":\"TNBC lacks standard targeted receptors, so chemotherapy remains the main strategy. However, chemotherapy faces poor tumor targeting, rapid systemic clearance, and significant off-target toxicity.\"},{\"question\":\"What therapeutic cargos do extracellular vesicles deliver in TNBC?\",\"answer\":\"Extracellular vesicles (EVs) can transport diverse therapeutic cargos, including chemotherapeutic agents and nucleic acids such as DNA and RNA, enabling targeted anti-tumor delivery.\"},{\"question\":\"What challenges affect clinical translation of EV-based therapies?\",\"answer\":\"Despite promising efficacy, clinical translation is hindered by technical limitations and inconsistent reporting, emphasizing the need for standardized protocols for EV isolation and characterization.\"}]","Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review | PDF",1790148818,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dcfd1382754a6cd433af230044d13b2.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9669aae35fec8ecd87e04888d3743aac.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31b21884791f4e2efed723e9b65dc57e.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc43394e9e5454cbfafa233c09de317.webp",980,1268]